2 results about "Diabetes model" patented technology

The application discloses application of Akkermansia muciniphila in preparation of a hypoglycemic product. Experiments prove that the Akkermansia muciniphila is Akkermansia muciniphila AkkTimepie001 with a preservation number of CCTCC NO: M 20231906, can effectively increase the body weight of a type 2 diabetes model mouse, improve the glucose tolerance capacity of the type 2 diabetes model mouse, and reduce the fasting blood glucose level, and confirms that the Akkermansia muciniphila has a significant blood glucose lowering effect.

The application discloses application of siRNA in preparation of postprandial hyperglycemia treatment preparation and belongs to the technical field of biology. By analyzing maltase-glucoamylase mRNA sequences of human and mice, siRNA sequences for silencing maltase-glucoamylase protein expression are designed, and unmodified siRNA and siRNA with 2'-OMe and 2'-F base modification are synthesized. The two kinds of siRNA are transfected into human small intestinal mucosal epithelial cells by liposomes, the silencing efficiency of the unmodified siRNA on the MGAM gene is 81.54%, and the silencing efficiency of the siRNA with base modification on the MGAM gene is 82.09%. The two kinds of siRNA are injected intravenously into type 2 diabetes model mice, and the expression of maltase-glucoamylase can be effectively silenced, postprandial hyperglycemia is reduced, the stability of the siRNA with base modification is improved, the drug efficacy time can be prolonged, and the drug use frequency is reduced.